Document is current

Article History

Received: 4 June 2021

Accepted: 21 September 2022

First Online: 19 October 2022

Declarations

:

: Liquid-based cytology samples processed in the capital region of Stockholm in Sweden are biobanked through a state-of-the-art platform at the Karolinska University Laboratory, Karolinska University Hospital. Ethical approval for use of samples and linked disease status information in the current study was granted by the Karolinska Ethical Committee (Dnr 2014/1242-31/4), which determined that study-specific informed consent from the study participants was not required due to the re-use of pseudonymized samples collected through population-based screening where women have already consented to have their sample available for ethically approved research studies, unless the woman chooses to opt out of such use. In the written invitation to screening issued by their Regional Cancer Centre, women are informed that by participating in cervical screening, they consent to the diagnosis of said sample as well as possible re-use of the samples for medical research approved by the Ethical Review Authority of Sweden. They are also actively informed of how to opt out from said sample biobanking and re-use procedure through their nearest biobank coordination center in their region. This provision is in accordance with the Swedish Biobank Law SFS number 2002:297. The research conformed to the principles of the Helsinki Declaration.

: Not applicable.

: J.E.B., A.J., I.E., and M.W. are named as inventors on a patent (submitted by UCLB, UCL’s technology transfer organization) which partly covers aspects described in this paper. J.E.B., C.H., and M.W. are shareholders of Sola Diagnostics GmbH, which holds an exclusive license to the intellectual property that protects the commercialization of the WID-CIN test. The remaining authors declare that they have no competing interests.